The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Myriad Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Teva (Inst)
The adjuvant PANTHER study: A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxel—Health-related quality of life during ongoing therapy.
 
Yvonne Brandberg
No Relationships to Disclose
 
Hemming Johansson
No Relationships to Disclose
 
Mats Hellstrom
No Relationships to Disclose
 
Theodoros Foukakis
No Relationships to Disclose
 
Michael Gnant
Employment - Sandoz (I)
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; NanoString Technologies; Novartis; Roche
Consulting or Advisory Role - Accelsiors; AstraZeneca; Novartis
Speakers' Bureau - Amgen; AstraZeneca; GlaxoSmithKline; NanoString Technologies; Novartis; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi; Smiths Medical
 
Gunter von Minckwitz
No Relationships to Disclose
 
Jonas C. S. Bergh
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)